Research just published by Zitter Health Insights, indicates that
uninsured consumers’ willingness to pay for health insurance in the exchanges is notably lower than the out of
pocket costs they would have to bear within the available marketplace plans.
In a November 4th article, the New York Times heralded the arrival of a new generation of Hepatitis C drugs as “an enormous public health achievement.” Indeed, over the next few years several drugs are expected to come to market that significantly aim to improve patient outcomes. But how will payers respond to new entrants in what […]read more
What does it mean when an insurer says it offers plans “in” a state? Does that mean everyone in the state can buy that plan? Unfortunately not. Insurers may elect to offer their plans in a certain geographic region, and some regions are more favorable demographically than others to insurers. Let’s take the case of […]read more
HEP C: STAKEHOLDERS PREPARE FOR INTERFERON-FREE REGIMENS AND USPSTF RECOMMENDATION ON SCREENING Understanding how stakeholders intend to respond may lead to delivery of better care. November 12, 2013, San Francisco, CA – The approval of interferon-free regimens to treat Hepatitis C is expected to change the care paradigm for millions of U.S. patients. Patients who […]read more
Now that a full month has passed since the opening of the Health Exchange Marketplace, there has been some more clarity into the variety of plans available. What is still somewhat unclear, is the impact that all these plan types may have on patient access to specialty medications. For example: Ambetter offers a gold plan […]read more